Novel Recombinant Rabies Vaccine Also Capable of Immunocontraception


This invention relates to a recombinant, attenuated rabies vaccine that is also capable of inhibiting reproductive fertility. An Evelyn-Rokitnicki-Abelseth (ERA) rabies vaccine backbone, combined with a reproductive-specific protein, such as gonadotropin-releasing hormone (GnRH) or the sperm-binding zona-pellucida-glycoprotein-3 (ZP3) receptor, allows reduction in both rabies transmission and uncontrolled reproduction in stray animals. The ERA rabies vaccine backbone has previously shown strong efficacy in animal studies. This vaccine may be delivered via injection or orally, including in an animal's food.

Potential Commercial Applications: Competitive Advantages:
  • Development of rabies and immunocontraceptive vaccines
  • Immunogenic compositions for both prevention and treatment of rabies virus
  • Animal welfare initiatives and rabies vaccination programs
 
  • Live, attenuated rabies vaccines show greater efficacy than older, inactivated rabies vaccine in prior animal studies
  • Potential for oral delivery, enabling vaccination of feral and difficult-to-reach animal populations
  • Novel approach to simultaneously addressing rabies transmission and uncontrolled wild animal reproduction


Development Stage:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Related Invention(s):




Inventors:

Xianfu Wu (CDC)  ➽ more inventions...

Charles Rupprecht (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8,524,247 issued 2012-09-03
PCT Application No. PCT/US2009/054502
US Application No. 13/062,680

Publications:
Wu X, et al. PMID 19925954

Licensing Contact:
Tara Kirby, Ph.D.
Email: tara.kirby@nih.gov
Phone: 240-669-5128

OTT Reference No: E-298-2013/0
Updated: Sep 19, 2013